A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT

THE PRESENT INVENTION GENERALLY RELATES TO PHARMACEUTICAL COMPOSITIONS CONTAINING A PROTEASE PROENZYME AND USE THEREOF FOR TREATING CANCER. THE PHARMACEUTICAL COMPOSITIONS ARE DIRECTED TO COMPOSITIONS COMPRISING A PROTEASE PROENZYME AND AN ACTIVE AGENT, THE COMPOSITION BEING CAPABLE OF PROVIDING A MULTI-FUNCTIONAL APPROACH FOR TREATING CANCER. THE PHARMACEUTICAL COMPOSITIONS ARE ALSO DIRECTED TO COMPOSITIONS COMPRISING A FIRST AND A SECOND PROTEASE PROENZYME CAPABLE OF ACTIVATION AT OR NEAR A SURFACE OF A TUMOUR CELL TO ENHANCE CELL-TO-CELL ADHESION OF TUMOUR CELLS, EFFECT PROTEOLYSIS OF TUMOUR CELLS, OR INDUCE TUMOUR CELL APOPTOSIS, DIFFERENTIATION OR IMMUNORECOGNITION, WHEREIN THE FIRST PROTEASE PROENZYME IS CHYMOTRYPSINOGEN AND THE SECOND PROTEASE PROENZYME IS TRYPSINOGEN. THE PHARMACEUTICAL COMPOSITIONS ARE ALSO DIRECTED TO COMPOSITIONS COMPRISING A FIRST AND SECOND ACTIVE AGENT EACH CAPABLE OF INDUCING INTRACELLULAR ACTIVITY IN TUMOUR CELLS.